Azitra, Inc. Announces Full Year 2023 Financial Results and Provides Business Updates
[ad_1]
BRANFORD, Conn.–(BUSINESS WIRE)–Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2023, and provided a business update. FY 2023 and Recent Business Highlights Completed an initial public offering, raising $7.5 million in gross proceeds. Obtained IND clearance of ATR-12 for a Phase 1b clinical trial in Netherton syndrome. Compl
[ad_2]
